Show simple item record

dc.contributor.authorPalmieri, C
dc.contributor.authorMisra, Vivek
dc.contributor.authorJanuszewski, A
dc.contributor.authorYosef, H
dc.contributor.authorAshford, R
dc.contributor.authorKeary, I
dc.contributor.authorDavidson, N
dc.date.accessioned2014-06-11T08:47:04Z
dc.date.available2014-06-11T08:47:04Z
dc.date.issued2014-04
dc.identifier.citationMulticenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer. 2014, 14 (2):85-93 Clin Breast Canceren
dc.identifier.issn1938-0666
dc.identifier.pmid24325950
dc.identifier.doi10.1016/j.clbc.2013.10.011
dc.identifier.urihttp://hdl.handle.net/10541/320674
dc.description.abstractThis study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical breast canceren
dc.titleMulticenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdomen
dc.identifier.journalClinical Breast Canceren
html.description.abstractThis study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability.


Files in this item

This item appears in the following Collection(s)

Show simple item record